Duloxetine
Product Images NDC 55154-2341

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 55154-2341). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (26e7c5d9 F191 43d5 81c8 E6cf1fcb3986 00)

Label for Duloxetine delayed-release capsules USP, 60 mg strength, in a package of 10 capsules. The label includes dosage information, storage instructions, and warnings about child resistance and institutional use. It lists distribution by Rising Health, Major Pharmaceuticals, and Cardinal Health, with manufacturing in India.*

FDA Label Image

Bag Label (26e7c5d9 F191 43d5 81c8 E6cf1fcb3986 01)

Duloxetine delayed-release capsules USP 30 mg in a 10-capsule unit dose package bearing the NDC 55154-2342-0. The label includes storage instructions, a warning that the package is not child resistant and is for institutional use only, and distributor information for Rising Health, MAJOR Pharmaceuticals, and Cardinal Health 107, LLC.*

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A line graph comparing the proportion of patients with relapse over time (days) between placebo and Duloxetine treatment groups. The y-axis represents the proportion of patients relapsing, ranging from 0 to 1, and the x-axis shows time from randomization to relapse in days, up to 250 days. Two lines represent relapse rates for placebo (dashed) and Duloxetine (solid).*

FDA Label Image

Figure-2 (Duloxetine Fig2)

A Kaplan-Meier survival curve graph illustrating the proportion of patients with relapse over time in days. The graph compares two treatments: Duloxetine and placebo, showing time from randomization to relapse on the x-axis and proportion of patients with relapse on the y-axis.*

FDA Label Image

Figure-3 (Duloxetine Fig3)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine at 60 mg twice daily (BID), 60 mg once daily (QD), 20 mg QD, and placebo. The graph shows declining improvement percentages as pain improvement thresholds increase.*

FDA Label Image

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Duloxetine Fig4)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The graph illustrates comparative improvement trends across these three groups over increasing pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine Fig5)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg administered twice daily, once daily, and placebo. The graph shows three lines representing each group, with the x-axis indicating percent improvement in pain and the y-axis indicating the percentage of patients improved.*

FDA Label Image

Figure 6 (Duloxetine Fig6)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Duloxetine at 120 mg, 60 mg, and 20 mg once daily doses with placebo. The graph depicts patient improvement trends with decreasing pain levels across treatment groups.*

FDA Label Image

Figure 7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline (BOCF) ranging from 0 to 100%, while the y-axis represents the percentage of patients improved, ranging from 0 to 100%. Duloxetine shows higher patient improvement percentages across various pain improvement thresholds compared to placebo.*

FDA Label Image

Figure 8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved over various thresholds of percent improvement in pain from baseline. The graph shows two groups: patients taking Duloxetine 60 mg once daily and those taking a placebo. The x-axis represents percent improvement in pain (BOCF), and the y-axis represents the percentage of patients improved. The Duloxetine group consistently shows higher percentages of improvement compared to placebo across all thresholds.*

FDA Label Image

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Duloxetine Fig9)

A line graph comparing the percentage of patients improved on the y-axis to the percent improvement in pain from baseline on the x-axis (BOCF). Two lines are shown: one for Placebo (dotted line with crosses) and one for Duloxetine 60/120 mg once daily (solid line with diamonds), demonstrating the differences in patient improvement percentages at various pain reduction levels.*

FDA Label Image

Chemical Structure (Duloxetine Str)

Chemical structure diagram of Duloxetine hydrochloride showing its molecular arrangement including the phenyl and thiophene rings, and the methylamino group hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.